DaehanPharmaceutical KRX:023910KOSDAQ
대한약품 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days1
Articles tracked1since Sep 11
In Q2 2026, DaehanPharmaceutical reported revenue of ₩56.6bn, up 9.9% year on year, and operating profit of ₩8.1bn. DaehanPharmaceutical (대한약품) appeared in 0 Korean news articles and 1 DART filing over the past seven days.
Filing signals Dividend grower Insider buying Screener
DaehanPharmaceutical quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩56.6bn | +9.9% | ₩8.1bn margin 14.3% | ₩6.8bn |
| Q1 2026 | ₩52.7bn | +5.7% | ₩7.9bn margin 14.9% | ₩7.0bn |
| Q4 2025 derived | ₩51.1bn | -0.8% | ₩3.6bn margin 7.0% | ₩5.1bn |
| Q3 2025 | ₩56.2bn | +2.4% | ₩10.6bn margin 18.9% | ₩8.7bn |
| Q2 2025 | ₩51.5bn | +5.3% | ₩7.7bn margin 15.0% | ₩6.2bn |
| Q1 2025 | ₩49.9bn | +1.8% | ₩9.2bn margin 18.5% | ₩7.6bn |
| Q4 2024 derived | ₩51.4bn | +4.5% | ₩8.7bn margin 17.0% | ₩9.0bn |
| Q3 2024 | ₩54.8bn | +7.7% | ₩10.8bn margin 19.7% | ₩8.5bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
DaehanPharmaceutical top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.